-
Mashup Score: 0BioMarin Receives Approval for First Gene Therapy for Adults With Severe Hemophilia A - 10 month(s) ago
Approximately 2500 individuals in the United States could be eligible to receive valoctocogene roxaparvovec.
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 0
The FDA accepted a biologics license application resubmission for valoctocogene roxaparvovec as treatment for adults with severe hemophilia A, according to a press release from the agent’s manufacturer.The resubmitted BLA for valoctocogene roxaparvovec (BioMarin), an investigational adeno-associated virus (AAV) vector gene therapy, includes the company’s responses to all deficiencies
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
Hear how developers have approached various aspects of the extensive manufacturing process to ultimately bring new and innovative treatments into the hand of patients and where we as an industry still need to focus.
Source: marketing.statnews.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0FDA Issues CRL for Hemophilia A Gene Therapy - 4 year(s) ago
Valoctocogene roxaparvovec would be the first ever approved gene therapy to treat patients with hemophilia A.
Source: HCPLiveCategories: General Medicine News, Latest HeadlinesTweet
The #FDA has approved #BioMarin’s gene therapy, valoctocogene roxaparvovec, to treat certain adults with severe #hemophiliaA, as determined by FDA-approved testing. Read more! https://t.co/A8rVphlQXc https://t.co/0O6irNibUs